The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.
C. Marth
No relevant relationships to disclose
J. Alexandre
No relevant relationships to disclose
L. C. Hanker
No relevant relationships to disclose
C. Brown
No relevant relationships to disclose
J. Kaern
No relevant relationships to disclose
M. Heywood
No relevant relationships to disclose
A. Bonaventura
No relevant relationships to disclose
I. B. Vergote
No relevant relationships to disclose
S. Pignata
No relevant relationships to disclose
A. Ferrero
No relevant relationships to disclose
V. Gebski
No relevant relationships to disclose
M. Gropp
No relevant relationships to disclose
T. Skeie-Jensen
No relevant relationships to disclose
C. Giede
No relevant relationships to disclose
P. A. Vasey
No relevant relationships to disclose
C. Schauer
No relevant relationships to disclose
N. Reed
No relevant relationships to disclose
G. Ferrandina
No relevant relationships to disclose
R. Fossati
No relevant relationships to disclose
E. Pujade-Lauraine
No relevant relationships to disclose